{"id":3228,"date":"2026-08-25T09:00:00","date_gmt":"2026-08-25T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3228"},"modified":"2026-09-19T13:53:10","modified_gmt":"2026-09-19T17:53:10","slug":"astrals-misses-phase-ii-als-endpoints","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3228","title":{"rendered":"ASTRALS Misses Phase II ALS Endpoints"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Novartis<\/p>\n

Event Type<\/strong><\/p>\n

Phase II Trial Failure \/ Program Discontinuation<\/p>\n

Modality<\/strong><\/p>\n

TREM2-Stabilizing Monoclonal Antibody<\/p>\n

Asset<\/strong><\/p>\n

VHB937 (Lifonebart)<\/p>\n

Target<\/strong><\/p>\n

TREM2<\/p>\n

Disease Area<\/strong><\/p>\n

Amyotrophic Lateral Sclerosis<\/p>\n

Summary<\/h4>\n

Novartis discontinued VHB937, also known as lifonebart, in amyotrophic lateral sclerosis after the 251-participant Phase II ASTRALS study missed its primary and secondary endpoints. The company-issued community update was published August 25, 2026 and resurfaced through biotechnology media on September 16, outside the prior 14-day reconciliation window. Detailed efficacy, pharmacodynamic, subgroup, and safety results remain undisclosed and are expected at the ALS\/MND symposium in December.<\/p>\n

ASTRALS was a randomized, placebo-controlled, 40-week study of the TREM2-stabilizing antibody in adults with ALS. The registry’s primary outcome combined permanent assisted ventilation-free survival and ALSFRS-R using a joint-rank method. Novartis stated only that primary and secondary endpoints were not met and that ALS development would stop; it did not attribute failure to mechanism, exposure, target engagement, trial design, or safety.<\/p>\n

The ClinicalTrials.gov record remained “active, not recruiting” and had no results posting when rechecked, making it stale relative to the company letter. Novartis’ current pipeline continues to list lifonebart in Phase II Alzheimer’s development. Failure in ALS therefore does not prove failure of TREM2 biology in every disease or of the molecule in its remaining indication.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that TREM2 agonism did not produce clinically meaningful slowing of ALS progression in the tested population, dose, and duration. A global randomized study and failure across primary and secondary endpoints support that conclusion. Against a broad target-level rejection, public information omits exposure, cerebrospinal-fluid pharmacology, biomarker engagement, and genotype or disease-stage subgroups. A second interpretation is that biology may be context- or timing-dependent and the negative result may reflect inadequate CNS engagement or treatment too late in disease. That remains plausible but unsupported until pharmacology is disclosed.<\/p>\n

Company and Product Background<\/h4>\n

VHB937 is a Novartis-originated, fully human monoclonal antibody that stabilizes and activates TREM2, a microglial receptor implicated in phagocytosis, lipid handling, and neuroinflammation. The molecule is intended to reduce TREM2 shedding and enhance protective microglial functions. ALS is a heterogeneous fatal motor-neuron disease in which neuroimmune modulation may depend on disease stage, central nervous system exposure, and patient biology.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • This is a material negative ALS signal and a clear surveillance miss. The appropriate claim is indication-specific: VHB937 failed ASTRALS and ALS development stopped.<\/li>\n
  • Upgrades toward target failure if:<\/strong> December data show adequate CNS exposure and TREM2 pathway engagement without clinical or biomarker benefit across credible subgroups.<\/li>\n
  • Shifts toward execution\/design failure if:<\/strong> exposure or engagement was inadequate, enrollment enriched for late heterogeneous disease, or endpoint power was weak.<\/li>\n
  • Falsified as a class-wide conclusion by:<\/strong> convincing benefit from independent TREM2 agonists or from lifonebart in a biologically defined population.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a material negative ALS signal and a clear surveillance miss. The appropriate claim is indication-specific: VHB937 failed ASTRALS and ALS development stopped. Mechanistic causation cannot be assigned before the full dataset, and continued Alzheimer’s development means the asset itself has not been abandoned.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 — a 251-participant randomized neurodegeneration failure and program discontinuation. Importance:<\/strong> Negative — efficacy endpoints failed and ALS development ended. Confidence:<\/strong> High on facts (a company-issued community letter and registry confirm design and disposition); moderate-low on interpretation (full efficacy, safety, exposure, and biomarker data are not public).<\/p>\n","protected":false},"excerpt":{"rendered":"

    Novartis discontinued VHB937, also known as lifonebart, in amyotrophic lateral sclerosis after the 251-participant Phase II ASTRALS study missed its primary and secondary endpoints. The company-issued community update was published August 25, 2026 and…<\/p>\n","protected":false},"author":1,"featured_media":3242,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[792,48,791],"class_list":["post-3228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-als","tag-novartis","tag-trem2"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3228"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3228\/revisions"}],"predecessor-version":[{"id":3251,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3228\/revisions\/3251"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3242"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}